Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer

被引：6
|
作者：
Ros, Javier [1 ]
Elez, Elena [1 ]
机构：
[1] Vall DHebron Hosp, Med Oncol, Barcelona, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 172卷
关键词：
D O I：
10.1016/j.ejca.2022.06.026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：326 / 328
页数：3
相关论文
共 50 条
  • [1] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
    Sharma, Vinod
    Vanidassane, Ilavarasi
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 876 - 876
  • [2] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
    Roviello, Giandomenico
    D'Angelo, Alberto
    Petrioli, Roberto
    Roviello, Franco
    Cianchi, Fabio
    Nobili, Stefania
    Mini, Enrico
    Lavacchi, Daniele
    TRANSLATIONAL ONCOLOGY, 2020, 13 (09):
  • [3] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
    Kopetz, S.
    Grothey, A.
    Yaeger, R.
    Van Cutsem, E.
    Desai, J.
    Yoshino, T.
    Wasan, H.
    Ciardiello, F.
    Loupakis, F.
    Hong, Y. S.
    Steeghs, N.
    Guren, T. K.
    Arkenau, H. -T.
    Garcia-Alfonso, P.
    Pfeiffer, P.
    Orlov, S.
    Lonardi, S.
    Elez, E.
    Kim, T. -W.
    Schellens, J. H. M.
    Guo, C.
    Krishnan, A.
    Dekervel, J.
    Morris, V.
    Calvo Ferrandiz, A.
    Tarpgaard, L. S.
    Braun, M.
    Gollerkeri, A.
    Keir, C.
    Maharry, K.
    Pickard, M.
    Christy-Bittel, J.
    Anderson, L.
    Sandor, V.
    Tabernero, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (17): : 1632 - 1643
  • [4] Molecular characterization and subsequent treatments after encorafenib-cetuximab plus /- binimetinib in BRAF V600E-mutated colorectal cancer.
    Ros Montana, Javier
    Navarro, Victor
    Comas, Raquel
    Garcia, Ariadna
    Saoudi Gonzalez, Nadia
    Baraibar, Iosune
    Salva, Francesc
    Vivancos, Ana
    Tabernero, Josep
    Elez, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer Reply
    Kopetz, Scott
    Grothey, Axel
    Tabernero, Josep
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 877 - 878
  • [6] Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab plus /-binimetinib (E-C plus /-B)
    Montana, F. J. Ros
    Navarro, V.
    Comas, R.
    Rodriguez, A. Garcia
    Gomez, D.
    Gonzalez, N. Saoudi
    Vicente, P.
    Cuadra, J. L.
    Paez, D.
    Alonso, V.
    Martinez, A. Hernandez
    Valbuena, D. E. Lopez
    Argota, I. Baraibar
    Ballabrera, F. Salva
    Tabernero, J.
    Fernandez, M. E. Elez
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S707 - S707
  • [7] Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
    Ros, Javierd
    Saoudi, Nadia
    Baraibar, Iosune
    Salva, Francesc
    Tabernero, Josep
    Elez, Elena
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [8] Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 199 - 202
  • [9] Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer
    Stammler, Romain
    Gallois, Claire
    Taieb, Julien
    Duong, Jean-Paul
    Karras, Alexandre
    Thervet, Eric
    Lazareth, Helene
    EUROPEAN JOURNAL OF CANCER, 2021, 147 : 60 - 62
  • [10] Treatment of metastatic BRAF-V600E mutated colorectal Carcinoma
    Pamuk, Aylin
    Zander, Thomas
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2020, 26 (03): : 292 - 294
12345